Holen Sie sich die Stockscreener-App
69.31
5.32%
3.50
Handel nachbörslich:
70.00
0.69
+1.00%
Schlusskurs vom Vortag:
$65.81
Offen:
$65.94
24-Stunden-Volumen:
1.21M
Relative Volume:
1.28
Marktkapitalisierung:
$4.74B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-146.66M
KGV:
-25.17
EPS:
-2.7541
Netto-Cashflow:
$-133.21M
1W Leistung:
+11.56%
1M Leistung:
-10.74%
6M Leistung:
+88.86%
1J Leistung:
+95.24%
1-Tages-Spanne:
$65.91
$70.10
1-Wochen-Bereich:
$60.35
$70.10
52-Wochen-Spanne:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
69.31 | 4.50B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-12-17 | Eingeleitet | Stephens | Overweight |
| 2025-12-10 | Eingeleitet | Deutsche Bank | Buy |
| 2025-11-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-07 | Bestätigt | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
APGE: Quarterly dosing, rapid itch relief, and strong safety set up a 2029 launch to challenge market leaders - TradingView
Candriam S.C.A. Invests $5.01 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics stock hits 52-week high at 62.24 USD By Investing.com - Investing.com South Africa
Apogee Therapeutics stock hits 52-week high at 62.24 USD - Investing.com
Smart Money: Should I set a stop loss on Lichen International LimitedEarnings Growth Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (APGE) Edition - Stock Traders Daily
Portfolio Update: What is Apogee Therapeutics Incs 5 year growth outlook2025 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CMO sells $361,860 in shares By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns By Investing.com - Investing.com Canada
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns - Investing.com
What drives Apogee Therapeutics Inc.’s stock priceEarnings Overview Summary & Low Risk Entry Point Tips - mfd.ru
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Aug Gainers: Can Apogee Therapeutics Inc stock outperform in a bear marketWeekly Stock Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling A 49.24% Upside In Biotech - DirectorsTalk Interviews
Does Apogee Therapeutics Inc. meet Warren Buffett’s criteriaEntry Point & Consistent Return Investment Signals - mfd.ru
(APGE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Shorts: What are TrueBlue Incs growth leversGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Promising Biotech Stocks To ResearchJanuary 24th - MarketBeat
Aug Breakouts: Whats the RSI of Adicet Bio Inc stockPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million By Investing.com - Investing.com Nigeria
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Trading Down 10.2% Following Insider Selling - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Director Fairmount Funds Management Llc Sells 1,750,000 Shares - MarketBeat
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns - Investing.com India
RBC Downgrades Apogee Therapeutics to Sector Perform From Outperform, Raises Price Target to $83 From $70, Keeps Speculative Risk - marketscreener.com
Apogee Therapeutics: 2026 Inflection Point In Immunology (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Biotech Gem with a 27.70% Upside Potential - DirectorsTalk Interviews
Bear Alert: Whats the beta of Apogee Therapeutics Inc stock2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Henderson sells $1.6m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Henderson sells $1.6m in stock - Investing.com
Price-Driven Insight from (APGE) for Rule-Based Strategy - Stock Traders Daily
What are Apogee Therapeutics Incs growth leversJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Apogee's Pipeline Momentum Driving Investor Confidence? - RTTNews
Apogee Therapeutics stock hits all-time high at 81.0 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's Why - MarketBeat
Apogee Therapeutics stock hits all-time high at 81.0 USD - Investing.com
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apogee Therapeutics Inc-Aktie (APGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Feb 04 '26 |
Option Exercise |
22.86 |
4,125 |
94,298 |
216,648 |
| Dambkowski Carl | Chief Medical Officer |
Feb 04 '26 |
Sale |
65.79 |
5,500 |
361,860 |
211,148 |
| Henderson Jane | Chief Financial Officer |
Feb 02 '26 |
Sale |
65.81 |
2,000 |
131,630 |
183,371 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
76.30 |
1,750,000 |
133,525,000 |
298,647 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):